2-[(6S,12R,15S,20S,23S,26S,28R)-23-(2-amino-2-oxoethyl)-20-carbamoyl-28-hydroxy-6-[(4-hydroxy-3-nitrophenyl)methyl]-2,5,8,11,14,22,25-heptaoxo-15-[[4-(trifluoromethyl)phenyl]carbamoylamino]-17,18-dithia-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacosan-12-yl]acetic acid | 1195753-80-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[(6S,12R,15S,20S,23S,26S,28R)-23-(2-amino-2-oxoethyl)-20-carbamoyl-28-hydroxy-6-[(4-hydroxy-3-nitrophenyl)methyl]-2,5,8,11,14,22,25-heptaoxo-15-[[4-(trifluoromethyl)phenyl]carbamoylamino]-17,18-dithia-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacosan-12-yl]acetic acid
• CAS: 1195753-80-0
• 化学式: C₄₀H₄₇F₃N₁₂O₁₆S₂
• 分子量: 1073.01
• InChiKey: ATHVQSHCJONDRS-NBPWXQSNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.1
• 重原子数：
  73
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  496
• 氢给体数：
  13
• 氢受体数：
  21

反应信息

• 作为产物：
  描述：

  在 碳酸氢铵 、 甲烷 作用下， 生成 2-[(6S,12R,15S,20S,23S,26S,28R)-23-(2-amino-2-oxoethyl)-20-carbamoyl-28-hydroxy-6-[(4-hydroxy-3-nitrophenyl)methyl]-2,5,8,11,14,22,25-heptaoxo-15-[[4-(trifluoromethyl)phenyl]carbamoylamino]-17,18-dithia-1,4,7,10,13,21,24-heptazabicyclo[24.3.0]nonacosan-12-yl]acetic acid
  参考文献：
  名称：

  Structure −Activity Relationship Studies of Targeting Ligands against Breast Cancer Cells

  摘要：

  A series of LXY3 (1) analogues were designed and synthesized. Their binding affinity was demonstrated using MDA-MB-231 breast cancer cells adherence inhibition assay. Further structure-activity relationship was obtained. Analogue 29 was discovered to have 3.5-fold increase of the binding affinity. Fluorescent microscopy and in vivo and ex vivo imaging studies demonstrated that 29 is tin efficient in vivo targeting agent against alpha 3 integrin of MDA-MB-231 breast tumor xenograft implant.

  DOI：

  10.1021/jm9012032